AURORIX

This brand name is authorized in Austria, Australia, Germany, Estonia, Finland, Hong Kong, Malta, Netherlands, New Zealand, Poland, Turkey

Active ingredients

The drug AURORIX contains one active pharmaceutical ingredient (API):

1 Moclobemide UNII PJ0Y7AZB63 - MOCLOBEMIDE

Moclobemide is an antidepressant which affects the monoaminergic cerebral neurotransmitter system by means of a reversible inhibition of monoamine oxidase preferentially of type A (RIMA). Read about Moclobemide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06AG02	Moclobemide	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AG Monoamine oxidase A inhibitors
Discover more medicines within N06AG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1900B, 8003F
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 00202502, 00210884, 04275260, 04275277, 07258285, 07266528
Country: EE	Ravimiamet	Identifier(s): 1421929, 1601918, 1764840
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 466813, 587857
Country: HK	Department of Health Drug Office	Identifier(s): 35868
Country: MT	Medicines Authority	Identifier(s): AA565/56901, AA565/56902
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 33340, 42978
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 3573, 3574
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100008323, 100053513
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699525094582, 8699525094599